---
title: "Impact of Coronary Artery Disease Extent on GRACE Risk Score Prognostic Performance After STEMI"
id: "journal-of-the-american-heart-association-56-impact-of-coronary-artery-disease-extent-on-grace-risk-score-prognostic-performance-after-st-segment-elevation-myocardial-infarction"
canonical_url: "https://medichelpline.com/clinical-feed/journal-of-the-american-heart-association-56-impact-of-coronary-artery-disease-extent-on-grace-risk-score-prognostic-performance-after-st-segment-elevation-myocardial-infarction"
content_type: "clinical_feed_article"
specialty: "Cardiology"
source_name: "Journal of the American Heart Association"
source_url: "https://www.ahajournals.org/doi/abs/10.1161/JAHA.125.047124?ai=sg&mi=3&af=R"
published_at: "2026-03-10T10:41:44.000Z"
evidence_level: "Journal Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# Impact of Coronary Artery Disease Extent on GRACE Risk Score Prognostic Performance After STEMI
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/journal-of-the-american-heart-association-56-impact-of-coronary-artery-disease-extent-on-grace-risk-score-prognostic-performance-after-st-segment-elevation-myocardial-infarction
- **Specialty:** [Cardiology](https://medichelpline.com/clinical-feed/cardiology.md)
- **Primary Source:** Journal of the American Heart Association
- **Source URL:** [Original Journal Publication](https://www.ahajournals.org/doi/abs/10.1161/JAHA.125.047124?ai=sg&mi=3&af=R)
- **Published At:** 2026-03-10T10:41:44.000Z
- **Evidence Rating:** Journal Feed
## Executive GIST (TL;DR)
Journal of the American Heart Association, Volume 15, Issue 6 , March 17, 2026. BackgroundThe GRACE (Global Registry of Acute Coronary Events) score is well validated for risk stratification in non–ST‐segment–elevation myocardial infarction, but less well established in ST‐segment–elevation myocardial infarction (STEMI), particularly relative to coronary disease burden. We therefore assessed its prognostic performance in a STEMI cohort, accounting for baseline coronary disease extent.MethodsWe studied 1099 patients with STEMI from the CardioLines Coronary Biobank (2015–2021) with evaluable GRACE score and follow‐up data. Patients were stratified by the number of coronary vessels with significant stenosis. The primary end point was all‐cause death at 1 year; the secondary end point was a combined end point, including all‐cause death, recurrent acute coronary syndrome, stroke, and revascularization at 1 year.ResultsMean GRACE scores increased with the number of diseased vessels (P<0.001). In multivariable models, each 10‐point increase in GRACE score was associated with a 31% higher risk of all‐cause death and a 14% higher risk of the combined end point at 1 year.
## Clinical Analysis & Structured Key Points
Journal of the American Heart Association published a clinical update in Cardiology on 10 Mar 2026. The item focuses on Impact of Coronary Artery Disease Extent on GRACE Risk Score Prognostic Performance After ST‐Segment–Elevation Myocardial Infarction. Review the original article for the full source wording and details.
## Related Clinical Research

- [Optimal DAPT Duration After PCI with Contemporary DES: Network Meta-analysis of RCTs](https://medichelpline.com/clinical-feed/plos-one-7-dual-antiplatelet-therapy-duration-after-percutaneous-coronary-intervention.md)
- [Stepwise DAPT de-escalation vs standard DAPT after drug-coated balloon angioplasty in multivessel](https://medichelpline.com/clinical-feed/medrxiv-15-impact-of-stepwise-dual-antiplatelet-therapy-de-escalation-in-patients-with.md)
- [Intracoronary prourokinase for slow‑flow/no‑reflow during PCI in ACS: randomized double‑blind tria](https://medichelpline.com/clinical-feed/bmj-open-5-efficacy-and-safety-of-intracoronary-injection-of-recombinant-human.md)
- [Ticagrelor versus Prasugrel After PCI for Acute Coronary Syndrome: Multinational Comparative Effec](https://medichelpline.com/clinical-feed/medrxiv-23-comparative-effectiveness-of-ticagrelor-vs-prasugrel-in-patients-with-acute.md)
- [Semaglutide and Primary Prevention of MACCE in Obese Adults with T2DM and Rheumatoid Arthritis](https://medichelpline.com/clinical-feed/pubmed-42334436.md) (DOI: 10.1093/ehjcvp/pvag044)

## Navigation
- [← Back to Cardiology Feed](https://medichelpline.com/clinical-feed/cardiology.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.